Description

Lornoxicam is a potent NSAID of the oxicam class, known for its strong analgesic, anti?inflammatory, and antipyretic effects. It inhibits both COX?1 and COX?2 enzymes, reducing prostaglandin synthesis. Lornoxicam Injection (brand name Zexi) contains 8?mg per sterile vial, formulated specifically for laboratory research use.

Produced by Suzhou Tianma Tianji Biopharma Co., Ltd., this product is approved for research under China’s NMPA number H20113080, with national drug code 86901669000427.

?? Strictly for laboratory research purposes. Not approved for clinical, veterinary, or diagnostic use.

Lornoxicam Injection Product Specifications

Lornoxicam Injection Mechanism & Research Applications

Lornoxicam inhibits both cyclooxygenase enzymes (COX?1 and COX?2), reducing synthesis of prostaglandins and thromboxane. This dual inhibition results in potent analgesic, anti?inflammatory, and antipyretic effects, without shifting metabolism toward leukotriene production. —Derived from structured pharmacological data.

Typical research applications include:

• In vitro and in vivo models of inflammation and pain

• Enzyme assays involving prostaglandin pathways

• Preclinical testing of analgesic efficacy

• Comparative assessments with other NSAIDs

• Pharmacokinetic and pharmacodynamic studies in animal models

Lornoxicam Injection Safety & Handling

• Intended Use: Laboratory research only; not approved for clinical or veterinary use

• Handling: Use lab-grade PPE—gloves, protective eyewear, and sterile handling conditions

• Storage: Maintain between 2–8?°C. Avoid freezing or prolonged light exposure

• Disposal: Dispose of according to local institutional biosafety protocols

Research Use Disclaimer

This product is strictly for laboratory research use. It is not intended or approved for therapeutic, clinical, diagnostic, or veterinary applications. Misuse may pose health and regulatory risks. Always follow institutional biosafety and safe handling procedures.